Cerity Partners LLC Increases Position in Integer Holdings Co. (NYSE:ITGR)

Cerity Partners LLC lifted its position in shares of Integer Holdings Co. (NYSE:ITGR) by 11.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,961 shares of the medical equipment provider’s stock after purchasing an additional 3,389 shares during the period. Cerity Partners LLC owned about 0.10% of Integer worth $4,285,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ITGR. Driehaus Capital Management LLC lifted its holdings in Integer by 62.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 353,052 shares of the medical equipment provider’s stock worth $40,880,000 after buying an additional 135,750 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in Integer during the third quarter worth approximately $14,403,000. F M Investments LLC acquired a new position in Integer in the second quarter valued at approximately $11,143,000. Point72 Europe London LLP purchased a new position in Integer in the second quarter valued at approximately $6,241,000. Finally, Earnest Partners LLC raised its holdings in Integer by 3.2% during the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock worth $139,911,000 after purchasing an additional 37,340 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Wall Street Analysts Forecast Growth

ITGR has been the topic of a number of recent analyst reports. Truist Financial dropped their target price on shares of Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Bank of America lifted their target price on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Benchmark upped their target price on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Citigroup lifted their price target on Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Finally, KeyCorp increased their price objective on Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $139.75.

Integer Price Performance

Integer stock opened at $140.80 on Friday. The business has a 50 day simple moving average of $131.15 and a 200-day simple moving average of $124.17. Integer Holdings Co. has a 12 month low of $84.75 and a 12 month high of $141.27. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The stock has a market capitalization of $4.72 billion, a PE ratio of 43.46, a price-to-earnings-growth ratio of 2.01 and a beta of 1.09.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, topping the consensus estimate of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The company had revenue of $431.42 million during the quarter, compared to analysts’ expectations of $440.59 million. During the same quarter last year, the business earned $1.27 EPS. The business’s revenue was up 8.7% on a year-over-year basis. Equities analysts predict that Integer Holdings Co. will post 5.34 earnings per share for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.